Arrivent Biopharma target price cut to $18 from $45 by Truist Securities
AVBP•Truist Securities cut its target price for Arrivent Biopharma to $18 from $45.
Related News
‘I'm getting fed up’: early US midterm voters line up before dawn in Ohio
SPY•
CrowdStrike CEO George Kurtz disposes of $5.25 million in Class A common stock
CRWD•
Nasdaq halts SUGP trading pending news at 7:50 p.m.
SUGP•
Vaxcyte prices $500 million convertible senior notes offering due 2032
PCVX•
US oil may extend bounce into $91.82-$92.53 range
USO•